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A 64-year-old male presented with a 6-month history of symmetric polyarthritis involving
proximal interphalangeal joints and metacarpophalangeal joints of the hands, wrists, and
ankles. Associated symptoms included vomiting, progressive fatigue, and weight loss.
Laboratory results showed microcytic anemia, leukocytosis, thrombocytosis, elevated
C-reactive protein and erythrocyte sedimentation rate, and rheumatoid factor (RF) and
anti-cyclic citrullinated protein (ACPA) antibody positivity. Joints radiographs were normal,
without erosions. Upper endoscopy and gastric endoscopic ultrasonography showed
a gastric adenocarcinoma with lymphatic involvement. Intraoperatively, peritoneal
carcinomatosis was documented, and the patient started palliative chemotherapy.
A paraneoplastic seropositive arthritis was assumed, and treatment with low-dose
prednisolone and hydroxychloroquine was started. Arthritis remission was achieved
and sustained up to 18 months of follow-up, although gastric cancer progression was
documented. We describe a unique phenotype of paraneoplastic arthritis (PA) presenting
as a seropositive (RF and ACPA positivity) rheumatoid arthritis (RA) with a good response
to both low dose corticosteroids and hydroxychloroquine therapy. We also review the
literature of PA, mostly the RA-like pattern, and the association between PA and ACPA
positivity. This case highlights the importance of considering underlying cancer in elderly
male patients, presenting with polyarthritis and systemic symptoms, even in those with
ACPA-positive RA-like arthritis.
Keywords: paraneoplastic syndrome, paraneoplastic arthritis, seropositive arthritis, rheumatoid arthritis, gastric
cancer
INTRODUCTION
Paraneoplastic syndromes are manifestations of a malignant disease that are not directly caused by
the tumor itself and occur distant from the primary tumor or metastasis. Temporal relationship
is the main critical issue to identify paraneoplastic syndromes, and as a rule, the manifestations
must occur during a malignant disease or precede it by no longer than 2 years (1–3). The best
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evidence for the association between the clinical manifestations
and the malignant disease is established retrospectively when the
symptoms improve or completely remit with the treatment of
the underlining neoplasm (1, 2). A spectrum of rheumatologic
manifestations can result from a paraneoplastic process and
are present in about 7–10% of patients with cancer, including
arthritis, lupus-like syndromes, inflammatory myopathies,
vasculitis, and hypertrophic osteoarthropathy (1, 3–5).
Paraneoplastic arthritis (PA) can present similarly to other
inflammatory arthritis, and some features are used to distinguish
it from those diseases. It affects more often elderly men
(male/female ratio of 1.7:1 and a median age of onset of 54 years)
and was classically described as a seronegative and non-erosive
asymmetrical oligo-polyarthritis involving most frequently the
knees, ankles, wrists, and hands (5–7). Recently, a symmetric
polyarthritis indistinguishable from rheumatoid arthritis (RA) as
a presenting feature of PA has been documented, and isolated
case reports of PA with rheumatoid factor (RF) and/or anti-
cyclic citrullinated peptide antibody (ACPA) positivity have been
published (4, 8–11). These data suggest that arthritis’ pattern
and serology may not be entirely reliable in the identification
of possible cases of PA (4). In this case-based review, we
report a gastric adenocarcinoma presenting as RA with RF and
ACPA positivity, and we review the literature of PA, mostly the
seropositive pattern.
CASE REPORT
A 64-year-old male presented to the emergency department
with a 6-month history of gradual onset of joint pain, swelling,
and morning stiffness involving the wrists, metacarpophalangeal
(MCP) joints, proximal interphalangeal (PIP) joints, and ankles.
In addition, he complained of occasional vomiting, anorexia,
progressive fatigue, and unintentional 12 kg of weight loss. His
arthralgia was progressive and debilitating, and had a poor
response to non-steroidal anti-inflammatory drugs (NSAIDs),
acetaminophen, and opioid analgesics (tramadol 200 mg daily).
His past medical history and medication were irrelevant
besides being an ex-smoker (10 pack-years, stopped 10 years
ago). He had a family history of gastrointestinal and pulmonary
malignancies. He denied any oral ulcers, dry eyes, rash, fever,
night sweats, gastrointestinal bleeding, or other complaints. On
physical examination, arthritis of the wrists, MCP joints, PIP
joints, and ankles, and a positive metatarsal squeeze test were
noted. The rest of the examination was unremarkable.
The initial laboratory investigations uncovered a microcytic
and hypochromic anemia (hemoglobin 7.9 g/dl), leukocytosis
(12.7 × 109/L), thrombocytosis (904 × 109/L), and elevation
of C-reactive protein (CRP; 17.3 mg/dl) and erythrocyte
sedimentation rate (ESR; 94 mm/h). Renal and liver profiles
were normal, and an infection screen was negative. An
anemia investigation showed low serum iron (9.6 µg/dl)
and transferrin saturation (4%), and normal ferritin (74.1
ng/dl), cyanocobalamin (465 pg/ml), and folate (5 ng/ml)
levels. Radiographic evaluation of the affected joints and
chest was unremarkable. The RF and ACPA were significantly
FIGURE 1 | Gastric mass on (A) upper gastrointestinal endoscopy and (B)
abdomen computed tomography (red arrow).
elevated at 215 IU/ml (0–14 IU/ml) and 156.9 IU/ml (<20
IU/ml), respectively.
Upper gastrointestinal endoscopy exhibited on the lesser
curvature and antrum of the stomach a hard and friable
mass with areas of necrosis that conditioned luminal stenosis
(Figure 1A). Endoscopy ultrasound of the upper gastrointestinal
tract revealed a mass extending 17mm to the serosa layer
with regional involvement of four lymph nodes. Endoscopy
biopsy specimens showed a gastric adenocarcinoma with
poor differentiation. Contrast-enhanced chest–abdomen–pelvis
computed tomography confirmed the gastric mass with no
evidence of other adenopathy or distant metastasis (Figure 1B),
and the tumor was rated T3N2M0, G3. Chest evaluation showed
slight changes compatible with emphysema.
During the hospitalization, while the malignancy workout
was ongoing, polyarthritis was treated with a short course of
corticosteroids (dexamethasone 5mg daily) with good clinical
response, and the dose was quickly tapered. However, a few
weeks later, his symptoms recurred, and he was readmitted
due to severe polyarthritis with disabling gait. Corticosteroid
therapy was reintroduced (prednisolone 20mg daily), and
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FIGURE 2 | Timeline disease activity of arthritis and relation with chemotherapy drugs, corticosteroids, and hydroxychloroquine. DAS28 3v-PCR, Disease Activity
Score for 28 joints with three variables (tender joint count, swollen joint count, and C-reactive protein); DEXA, dexamethasone; HCQ, hydroxychloroquine; PDN,
prednisolone.
hydroxychloroquine (200mg daily) was also added. However,
full adherence to the therapeutic regimen was only possible
after a few months and only then was a complete resolution of
polyarthritis achieved (Figure 2).
He was referred to oncology and proposed for gastrectomy.
During the laparotomy procedure, extensive peritoneal
carcinomatosis was detected, whereby he underwent
gastrojejunostomy. The patient started palliative chemotherapy
with cisplatin and fluorouracil, and after HER2 overexpression
was documented, trastuzumab was added. Cisplatin and
fluorouracil were stopped after 8 months, but cancer progression
was documented and were reintroduced later on, with little effect
on arthritis control. After 18 months of follow-up, he remained
alive, with sustained arthritis remission for over 9 months
(documented clinically and using ultrasound) and without
radiological detectable erosions, under treatment with low-dose
prednisolone (<7.5mg daily) and hydroxychloroquine (300mg
daily), despite the absence of a curative cancer treatment.
DISCUSSION
Overall, patients with RA are at an increased risk of cancer
compared with the general population. However, gastric cancer
has a lower incidence in RA patients, which can be explained
by the increased use of NSAIDs in this population (12–15). The
incidence of RA in patients with gastric cancer is not known.
A wide variety of solid and hematological malignancies has
been associated with PA, with lung adenocarcinoma being the
TABLE 1 | Traditional characteristics of paraneoplastic arthritis [adapted from
Stummvoll et al. (5), Larson et al. (8), Caldwell and McCallum (19), and
Pfitzenmeyer et al. (20)].
1. Close temporal relationship (12 months) between the
onset of arthritis and malignancy
2. Older age
3. Joint involvement in an asymmetric distribution
4. Predominance of lower extremity involvement
5. Explosive onset
6. Absence of family history of rheumatic disease
7. Absence of rheumatoid nodules
8. Absence of characteristic radiographic lesions of RA
9. Absence of RF
10. Non-specific histopathologic appearance of the
synovial lining
RA, rheumatoid arthritis; RF, rheumatoid factor.
most frequent (3, 9). Thus, far, only four patients with PA were
reported having gastric tumors, none with a seropositive RA-like
pattern (3, 16–18).
Based on the review of case reports, PA was traditionally
described as a seronegative asymmetric oligoarthritis with
predominant involvement of the lower limb joints (Table 1).
However, a symmetric polyarthritis indistinguishable from RA is
now recognized to be the most frequent pattern, in a few cases
associated with RF or ACPA.
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TABLE 2 | New characteristic features proposed for the diagnosis of
paraneoplastic arthritis [adapted from Morel et al. (3)].
1. Average time between arthritis and neoplasia diagnosis <6 months
2. Men age >50 years
3. Polyarthritis (symmetric or asymmetric)
4. Absence of rheumatoid nodules
5. Absence of erosions on radiography
6. Absence of RF
7. Degradation of general health status
8. High CRP level
9. Regression of arthritis after specific anti-tumoral therapy
CRP, C-reactive protein; RF, rheumatoid factor.
Classic PA features were detailed by Kisacik et al. (7) by
comparing patients with PA (n = 65) with patients diagnosed
with early RA (n= 50). In this study, the PA group was defined by
using previously described traditional features, and the inclusion
criteria were rapid disease onset and symmetric or asymmetric
disease mostly affecting the lower extremities and usually sparing
the small joints of the hands. Consequently, patients with RA-like
arthritis were excluded from the PA group, which originated an
unintentional bias in the description of PA characteristics.
An earlier study by Morel et al. better characterized this
type of arthritis, in a case series of 26 patients with PA, using
a less restrictive arthritis pattern—oligo-polyarthritis evolving
for a maximum of 2 years before cancer diagnosis (3). Despite
confirming most of the traditional features, such as the absence
of RF and radiologic lesions, they concluded that the majority of
patients displayed features of RA, being symmetric polyarthritis,
involving wrists and hands, the most frequent articular pattern
(85%). Therefore, they proposed a new group of characteristic
features for the diagnosis of PA (Table 2).
A review by Watson et al. also included several patients with
PA with symmetric distribution and involvement of the wrists,
small joints of the hands, and knees, resembling RA. Contrary to
previous reports, some of these patients were positive for both RF
and ACPA (9).
Our patient presented with an RA-like pattern and high
titer for both RF and ACPA meeting the 2010 American
College of Rheumatology/European League Against Rheumatism
classification criteria for RA. To the best of our knowledge, this
is the sixth case described in the literature classifiable as a PA
with RF and ACPA positivity (Table 3). Of interest, four of these
patients also had an RA-like pattern, with erosive arthritis present
in one of them. Most of the patients responded well to low-
dose corticosteroid therapy, but due to the advanced stage of
the malignancies, tumor therapy was curative in a single patient,
and only in this case, a complete resolution of the PA occurred.
None of the reported cases mentions the prescription of disease-
modifying anti-rheumatic drugs (DMARDs), which may be
explained by the concomitant chemotherapy or predictable poor
general condition of a patient with advanced neoplastic disease.
Despite the fact that PA was classically described as refractory
to corticosteroids and NSAIDs, the study by Morel et al. showed
some contradictory information. NSAIDs and corticosteroids
were effective, respectively, in 45 and 91% of the patients, but
without obtaining a sustained remission. DMARDs (sulfasalazine
and methotrexate) were only effective in one out of five
treated patients.
Two studies analyzed a series of patients with paraneoplastic
rheumatologic syndromes and showed that the majority of PA
were ACPA negative (7, 21). ACPA have similar sensitivity as
RF to RA but with a higher specificity (90–95%), thus, allowing
more accurate diagnosis of RA, especially in cases of early
undifferentiated arthritis (8, 9). However, this test is not 100%
specific, and ACPA positivity has been reported in a variety
of diseases (21–25). As this case highlights, the presence of
ACPA in the context of a polyarthritis should not exclude
automatically other diagnostic entities, particularly in elderly
patients with consumptive symptoms. Overlooking this might
delay the diagnosis and treatment of underlying cancer (8, 9).
ACPAs are formed against citrullinated antigens that
appear after enzyme-catalyzed peptide transformation by
peptidylarginine deiminase (PAD) enzymes. In RA, these
antigens are found in inflammatory synovial membranes, and
ACPAs have been shown to perpetuate joint inflammation and
correlate with more aggressive disease (26). In hematological
and solid tumors, PAD enzymes are upregulated and have been
implicated in the carcinogenesis process (27). In 2014, Handy
et al. proposed a possible association between ACPA positivity
and PA (4). They suggested that ACPA could appear due to
the overexpression of PAD enzymes in malignant diseases,
generating citrullinated peptides, which are then exposed to the
immune system. However, this hypothesis does not explain all
PA cases (as most are ACPA negative) nor offers a complete
mechanistic elucidation of the PA phenomena.
In the present case, the onset of a symmetric polyarthritis in an
elderly man, associated with constitutional symptoms and iron
deficiency anemia led us to an additional workup. In our opinion,
the characteristic features proposed by Morel et al. (3) (Table 2)
are more representative of the full spectrum of PA and should be
preferred in clinical practice.
Cancer progression was seen in our patient and was
accompanied by flares of polyarthritis, despite ongoing
chemotherapy. We should note that some chemotherapy drugs
can improve RA clinical manifestations, namely, cisplatin and
fluorouracil, which were used in this patient (28, 29). However,
in this case, chemotherapy drugs did only have a modest effect,
and arthritis remission was only possible when full adherence
to hydroxychloroquine and prednisolone was achieved. Since
the effect of hydroxychloroquine in monotherapy in RA is quite
modest when compared with other classic DMARDs, especially
in double seropositive RA, it is probable that in our patient,
the arthritis remission was achieved due to the combination of
hydroxychloroquine, prednisolone, and chemotherapy (30).
Accordingly, we believe our case represents a seropositive PA,
being the first case related to gastric malignancy. Unfortunately,
the staging of our patients’ malignant disease determined
palliative surgery and chemotherapy, and the likelihood of
curative treatment is very low. We cannot, thus, conclude if
arthritis would remit with the treatment of underlying cancer.















































TABLE 3 | Characteristic features of published cases of RF and ACPA-positive paraneoplastic arthritis.


































58/M Pancreatic cancer 2 N.M. No arthritis; arthralgia
involving hands, wrists,
elbows, shoulders,
lower back, and neck;
asymmetric and
intermittent





3–4 No Wrists, knees, and
ankles; symmetric





3 No PIP, MCP, elbows, and
knees; symmetric






1–2 No MCP, wrists, knees,
and ankles; symmetric



















6 Yes (GI and
lung)
PIP, MCP, wrists, and
ankles; symmetric
Gradual Yes ++/+++ ++/++ N.E. No Yes 5-FU and CIS
CMT (not
curative)
CPR, C-reactive protein; ESR, erythrocyte sedimentation rate; ACPA, anti-cyclic citrullinated peptide antibodies; RF, rheumatoid factor; NSAIDs, non-steroidal anti-inflammatory drugs; F, female; M, male; GI, gastrointestinal; MCP,
metacarpophalangeal joints; PIP, proximal interphalangeal joints; 5-FU, fluorouracil; CIS, cisplatin; hyper CVAD, cyclophosphamide, vincristine, doxorubicin, and dexamethasone; CMT, chemotherapy; RT, radiotherapy; N.E., no erosions;
N.M., not mentioned.
ESR: – if <30, + if ≥30, and <60, ++ if ≥60 and <100, +++ if ≥100.
CPR: + if ≥0.5 and <5.0, ++ if ≥5.0 and <15.0, +++ if ≥15.0.
RF titer: + if ≥14 and <100, ++ if ≥100 and <300, +++ if ≥300.
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In conclusion, our case illustrates that physicians
should be aware and rule out cancer in an ACPA-
positive RA-like polyarthritis in patients with
constitutional symptoms and/or with laboratory
features showing severe anemia, thrombocytosis, and
very high CRP.
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